OrbiMed’s 89bio ETNB Stock Holding History

OrbiMed’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,658,869	Closed	-$46.6M	–	131
2022 Q4	$46.6M	Hold	3,658,869	–	–	0.89%	42
2022 Q3	$21.2K	Hold	3,658,869	–	–	0.39%	65
2022 Q2	$11.8K	Hold	3,658,869	–	–	0.21%	85
2022 Q1	$13.8M	Sell	3,658,869 -70,573	-2%	-$455K	0.22%	87
2021 Q4	$48.7M	Hold	3,729,442	–	–	0.63%	49
2021 Q3	$73.1M	Hold	3,729,442	–	–	0.8%	39
2021 Q2	$69.7M	Hold	3,729,442	–	–	0.71%	46
2021 Q1	$88.3M	Hold	3,729,442	–	–	0.83%	36
2020 Q4	$90.9M	Hold	3,729,442	–	–	0.8%	41
2020 Q3	$95.7M	Sell	3,729,442 -275,000	-7%	-$8.72M	1.2%	23
2020 Q2	$79.8M	Hold	4,004,442	–	–	1.12%	29
2020 Q1	$101M	Hold	4,004,442	–	–	1.7%	18
2019 Q4	$105M	Buy	+4,004,442	New	+$111M	1.5%	18

Other funds holding ETNB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

OrbiMed's ETNB Position: Q1 2023 in Review

OrbiMed sold out of 89bio (ETNB) in Q1 2023, closing a stake of 3,658,869 shares — an estimated $46.6M sold.

OrbiMed first reported a position in ETNB in Q4 2019 and held it in 13 quarters. The position peaked at $105M in Q4 2019. 145 funds tracked by Wall St. Rank hold ETNB as of Q1 2023.

OrbiMed reported no remaining 89bio position as of Q1 2023 after selling out during the quarter.
OrbiMed sold 3,658,869 89bio shares in Q1 2023, an estimated $46.6M.
OrbiMed first reported a position in 89bio in Q4 2019 and held it in 13 quarters.
OrbiMed's 89bio position peaked at $105M in Q4 2019.
145 funds tracked by Wall St. Rank held 89bio as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.